Mylan has entered a global collaboration and license agreement with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19. The license agreement gives Mylan rights to manufacture and distribute remdesivir in 127 low- and middle-income countries, including India. The agreement is non-exclusive, allowing for multiple licensees to ensure extensive access to this treatment, once approved as safe and effective for COVID-19 patients. ...